GLYCINE

Search structure


Trade Names:	AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER GLYCINE 1.5% IN PLASTIC CONTAINER
Synonyms:	FEMA NO. 3287 GLICINA GLYCOLIXIR NSC-25936
Status:	Approved
Entry Type:	Small molecule
Molecule Category:	UNKNOWN
ATC:	B05CX03
UNII:	TE7660XO1C

Structure


InChI Key	DHMQDGOQFOQNFH-UHFFFAOYSA-N
Smile	NCC(=O)O
InChI	InChI=1S/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C2H5NO2
Molecular Weight	75.07
AlogP	-0.97
Hydrogen Bond Acceptor	2.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	1.0
Polar Surface Area	63.32
Molecular species	ZWITTERION
Aromatic Rings	0.0
Heavy Atoms	5.0

Pharmacology

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Transferase	-	-	-	-	11.23
Enzyme	-	-	-	366000	11.23
Epigenetic regulator Eraser Histone deacetylase HDAC class IIb	-	-	-	-	-9.25--5.09
Ion channel Ligand-gated ion channel Glycine receptor	94000-95499.26	-	-	-	-
Ion channel Ligand-gated ion channel Ionotropic glutamate receptor NMDA receptor	210-300	86-690	-	125.89-170	-
Membrane receptor Family A G protein-coupled receptor	58	-	-	-	-
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC03 and SLC07 families of heteromeric amino acid transporters (HATs) SLC07 Cationic amino acid transporter/glycoprotein-associated family	-	-	-	-	33-33
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC06 neurotransmitter transporter family	106000	1348962.88	-	-	49.3-69.7
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC36 family of proton-coupled amino acid transporters	-	-	-	5100000	-

Indications

Mesh Heading	Maximum Phase	Mesh ID	Reference
Malnutrition	3	D044342	ClinicalTrials
Diarrhea	3	D003967	ClinicalTrials
Schizophrenia	3	D012559	ClinicalTrials
Herpes Labialis	2	D006560	ClinicalTrials
Obsessive-Compulsive Disorder	2	D009771	ClinicalTrials
Psychotic Disorders	2	D011618	ClinicalTrials
Mental Disorders	2	D001523	ClinicalTrials
Respiratory Tract Diseases	2	D012140	ClinicalTrials
Herpes Simplex	2	D006561	ClinicalTrials
Hypertension	2	D006973	ClinicalTrials
Asthma	2	D001249	ClinicalTrials
Cystic Fibrosis	2	D003550	ClinicalTrials
Bipolar Disorder	2	D001714	ClinicalTrials
Cognitive Dysfunction	1	D060825	ClinicalTrials
Alzheimer Disease	1	D000544	ClinicalTrials
HIV Infections	1	D015658	ClinicalTrials
Severe Acute Respiratory Syndrome	1	D045169	ClinicalTrials

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
Nervous system disorders	16.67
Metabolism and nutrition disorders	13.33
Eye disorders	12.22
Injury, poisoning and procedural complications	11.11
Cardiac disorders	8.89
Investigations	7.78
Renal and urinary disorders	6.67
General disorders and administration site conditions	5.56
Respiratory, thoracic and mediastinal disorders	5.56
Gastrointestinal disorders	4.44
Vascular disorders	4.44

Cross References

Resources	Reference
CAS NUMBER	56-40-6
ChEBI	15428
ChEMBL	CHEMBL773
DrugBank	DB00145
DrugCentral	1319
EPA CompTox	DTXSID9020667
FDA SRS	TE7660XO1C
Human Metabolome Database	HMDB00123
Guide to Pharmacology	727
KEGG	C00037
PDB	GLY
PharmGKB	PA449789
PubChem	750
SureChEMBL	SCHEMBL6163
ZINC	ZINC000004658552

CONTENTS